Clinical Trials
38 trialsBrentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
M.D. Anderson Cancer Center
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
St. Jude Children's Research Hospital
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
PROMIT
University of Erlangen-Nürnberg Medical School
TNT-HYPE
Swiss Cancer Institute
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
BrECADD
University of Miami
TAGGED
Sarcoma Oncology Research Center, LLC
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
BREACH
The Lymphoma Academic Research Organisation
DTIC
University of Louisville
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma
N.N. Petrov National Medical Research Center of Oncology
(Optimist)
King Abdullah International Medical Research Center
SUAVE
The Clatterbridge Cancer Centre NHS Foundation Trust
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Metronomic Therapy in Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
University of Cologne
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
Peking University
Bevacizumab vs Dacarbazine in Metastatic Melanoma
Haukeland University Hospital
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Washington University School of Medicine
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Medical University of Vienna
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
University of Chicago
Rituximab and ABVD for Hodgkin's Patients
M.D. Anderson Cancer Center
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
American Scitech International
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
University of Zurich
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku